Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Insider Ashley Hall Sells 15,625 Shares of Stock

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) insider Ashley Hall sold 15,625 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $6.28, for a total value of $98,125.00. Following the completion of the sale, the insider now directly owns 39,600 shares in the company, valued at $248,688. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Reneo Pharmaceuticals Price Performance

NASDAQ:RPHM opened at $6.36 on Wednesday. Reneo Pharmaceuticals, Inc. has a 1 year low of $1.79 and a 1 year high of $11.30. The business has a fifty day moving average of $6.67 and a 200-day moving average of $6.70.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of RPHM. American International Group Inc. bought a new position in Reneo Pharmaceuticals during the second quarter valued at about $31,000. Wells Fargo & Company MN boosted its stake in Reneo Pharmaceuticals by 352.1% during the second quarter. Wells Fargo & Company MN now owns 5,715 shares of the company’s stock valued at $37,000 after buying an additional 4,451 shares in the last quarter. Renaissance Technologies LLC bought a new position in Reneo Pharmaceuticals during the second quarter valued at about $61,000. Dimensional Fund Advisors LP bought a new position in Reneo Pharmaceuticals during the third quarter valued at about $62,000. Finally, Tang Capital Management LLC bought a new position in Reneo Pharmaceuticals during the fourth quarter valued at about $71,000. Institutional investors own 85.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on RPHM shares. Bank of America started coverage on Reneo Pharmaceuticals in a research note on Monday, July 3rd. They issued a “buy” rating for the company. HC Wainwright started coverage on Reneo Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $30.00 price target for the company.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.